Literature DB >> 3871205

Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells.

M Schwyzer, A Fontana.   

Abstract

The human glioblastoma cell line 308 constitutively secretes a soluble factor with biologic and biochemical characteristics of human monocyte-derived interleukin 1 (IL 1). The 308 cells also produce a 97,000 m.w. factor that inhibits the effects of IL 1 and interleukin 2 (IL 2) on T lymphocytes. By using sequential chromatography on Blue Affigel, hydroxyapatite, and Ultrogel AcA54, the inhibitory factor, termed glioblastoma-derived T cell suppressor factor (G-TsF), was separated from IL 1 and purified 2000-fold with respect to the protein present in the crude 308 cell supernatant. This G-TsF preparation was sensitive to tryptic proteolysis, showed a peak of pI 4.6 on isoelectric focusing, and when labeled with 125I, revealed six protein bands in the range of 30 to 100 kdaltons on SDS gel.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871205

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.

Authors:  E Satoh; H Naganuma; A Sasaki; M Nagasaka; H Ogata; H Nukui
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

2.  Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).

Authors:  J F Balavoine; B de Rochemonteix; K Williamson; P Seckinger; A Cruchaud; J M Dayer
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

Review 3.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

Review 4.  Application of advances in molecular biology to the treatment of brain tumors.

Authors:  H Takeshima; Y Sawamura; M R Gilbert
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

5.  Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain.

Authors:  Chenyu Zhang; Fahao Zhang; Rachel Tsan; Isaiah J Fidler
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

6.  Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

Review 7.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

8.  Cell-mediated cytotoxicity in glioma-bearing patients: differential responses of peripheral blood mononuclear cells to stimulation with interleukin-2 and microbial antigen.

Authors:  C Ausiello; A Maleci; G C Spagnoli; G Antonelli; A Cassone
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

9.  Expression and release of interleukin-1 by human glioblastoma cells in vitro and in vivo.

Authors:  T Gauthier; M F Hamou; L Monod; P Gallay; S Carrel; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

10.  Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

Authors:  P A Ruffini; L Rivoltini; A Silvani; A Boiardi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.